Skip to main content
Erschienen in: Diabetologia 5/2006

01.05.2006 | Article

Effect of R-(+)-α-lipoic acid on experimental diabetic retinopathy

verfasst von: J. Lin, A. Bierhaus, P. Bugert, N. Dietrich, Y. Feng, F. vom Hagen, P. Nawroth, M. Brownlee, H.-P. Hammes

Erschienen in: Diabetologia | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Hyperglycaemia-induced mitochondrial overproduction of reactive oxygen species (ROS) is central to the pathogenesis of endothelial damage in diabetes. R-(+)-α-lipoic acid has advantages over classic antioxidants, as it distributes to the mitochondria, is regenerated by glycolytic flux, and has a low redox potential.

Methods

To assess the effect of R-(+)-α-lipoic acid on experimental diabetic retinopathy, three groups of male Wistar rats were studied: non-diabetic controls, untreated diabetic controls, and diabetic rats treated with 60 mg/kg bodyweight R-(+)-α-lipoic acid i.p. for 30 weeks. Quantitative retinal morphometry included acellular occluded capillaries and pericyte numbers. The effects of R-(+)-α-lipoic acid on parameters of oxidative and nitrative stress, AGE and its receptor and nuclear factor kappa B (NFκB) were assessed by immunoblotting, and NFκB activation by electrophoretic mobility shift assay. Angiopoietin-2 and vascular endothelial growth factors were also determined by immunoblotting.

Results

After 30 weeks of diabetes, the number of acellular capillaries was significantly elevated in diabetic rats (57.1±10.6 acellular capillary segments [ac]/mm2 of retinal area) compared with non-diabetic (19.8±5.1 ac/mm2; p<0.001). Treatment with 60 mg/kg R-(+)-α-lipoic acid reduced the numbers by 88% (p<0.001 vs diabetic). Pericyte loss was also significantly inhibited in diabetic rats treated with R-(+)-α-lipoic acid (non-diabetic: 1,940±137 pericytes/mm2capillary area; untreated diabetic: 1,294±94 pericytes/mm2capillary area vs treated diabetic: 1,656±134 pericytes/mm2; p<0.01). R-(+)-α-lipoic acid treatment reduced oxidative stress, normalised NFκB activation and angiopoietin-2 expression, and reduced vascular endothelial growth factor in the diabetic retina by 43% (p<0.0001).

Conclusions/interpretation

R-(+)-α-lipoic acid prevents microvascular damage through normalised pathways downstream of mitochondrial overproduction of ROS, and preserves pericyte coverage of retinal capillaries, which may provide additional endothelial protection.
Literatur
1.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986 The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
2.
Zurück zum Zitat UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853 UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
3.
Zurück zum Zitat Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedADS Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedADS
4.
Zurück zum Zitat Du X, Matsumura T, Edelstein D et al (2003) Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112:1049–1057PubMed Du X, Matsumura T, Edelstein D et al (2003) Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112:1049–1057PubMed
5.
Zurück zum Zitat Kaiser N, Sasson S, Feener EP et al (1993) Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 42:80–89PubMed Kaiser N, Sasson S, Feener EP et al (1993) Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 42:80–89PubMed
6.
Zurück zum Zitat Hammes HP, Du X, Edelstein D et al (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9:294–299PubMed Hammes HP, Du X, Edelstein D et al (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9:294–299PubMed
7.
Zurück zum Zitat Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003) Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52:2110–2120PubMed Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003) Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52:2110–2120PubMed
8.
Zurück zum Zitat Du Y, Miller CM, Kern TS (2003) Hyperglycaemia increases mitochondrial superoxide in retina and retinal cells. Free Radic Biol Med 35:1491–1499PubMed Du Y, Miller CM, Kern TS (2003) Hyperglycaemia increases mitochondrial superoxide in retina and retinal cells. Free Radic Biol Med 35:1491–1499PubMed
9.
Zurück zum Zitat Kowluru RA, Kern TS, Engerman RL, Armstrong D (1996) Abnormalities of retinal metabolism in diabetes or experimental galactosemia. III. Effects of antioxidants. Diabetes 45:1233–1237PubMed Kowluru RA, Kern TS, Engerman RL, Armstrong D (1996) Abnormalities of retinal metabolism in diabetes or experimental galactosemia. III. Effects of antioxidants. Diabetes 45:1233–1237PubMed
10.
Zurück zum Zitat Obrosova IG, Minchenko AG, Marinescu V et al (2001) Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 44:1102–1110PubMed Obrosova IG, Minchenko AG, Marinescu V et al (2001) Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 44:1102–1110PubMed
11.
Zurück zum Zitat Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259 Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259
12.
Zurück zum Zitat Mayer-Davis EJ, Bell RA, Reboussin BA, Rushing J, Marshall JA, Hamman RF (1998) Antioxidant nutrient intake and diabetic retinopathy: the San Luis Valley Diabetes Study. Ophthalmology 105:2264–2270PubMed Mayer-Davis EJ, Bell RA, Reboussin BA, Rushing J, Marshall JA, Hamman RF (1998) Antioxidant nutrient intake and diabetic retinopathy: the San Luis Valley Diabetes Study. Ophthalmology 105:2264–2270PubMed
13.
Zurück zum Zitat Hammes HP, Bartmann A, Engel L, Wülfroth P (1997) Antioxidant treatment of experimental diabetic retinopathy with nicanartine. Diabetologia 40:629–634PubMed Hammes HP, Bartmann A, Engel L, Wülfroth P (1997) Antioxidant treatment of experimental diabetic retinopathy with nicanartine. Diabetologia 40:629–634PubMed
14.
Zurück zum Zitat Liu J, Head E, Gharib AM et al (2002) Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-l-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci USA 99:2356–2361PubMedADS Liu J, Head E, Gharib AM et al (2002) Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-l-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci USA 99:2356–2361PubMedADS
15.
Zurück zum Zitat Hagen TM, Ingersoll RT, Lykkesfeldt J et al (1999) (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J 13:411–418PubMed Hagen TM, Ingersoll RT, Lykkesfeldt J et al (1999) (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J 13:411–418PubMed
16.
Zurück zum Zitat Bustamante J, Lodge JK, Marcocci L, Tritschler HJ, Packer L, Rihn BH (1998) Alpha-lipoic acid in liver metabolism and disease. Free Radic Biol Med 24:1023–1039PubMed Bustamante J, Lodge JK, Marcocci L, Tritschler HJ, Packer L, Rihn BH (1998) Alpha-lipoic acid in liver metabolism and disease. Free Radic Biol Med 24:1023–1039PubMed
17.
Zurück zum Zitat Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G (1998) Upregulation of the VEGF/VEGF-receptor system in experimental background diabetic retinopathy of the rat. Diabetes 47:401–406PubMed Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G (1998) Upregulation of the VEGF/VEGF-receptor system in experimental background diabetic retinopathy of the rat. Diabetes 47:401–406PubMed
18.
Zurück zum Zitat Lu M, Kuroki M, Amano S et al (1998) Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 101:1219–1224PubMed Lu M, Kuroki M, Amano S et al (1998) Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 101:1219–1224PubMed
19.
Zurück zum Zitat Raab S, Beck H, Gaumann A et al (2004) Vascular endothelial growth factor is essential for brain angiogenesis and development. Thromb Haemost 91:595–605PubMed Raab S, Beck H, Gaumann A et al (2004) Vascular endothelial growth factor is essential for brain angiogenesis and development. Thromb Haemost 91:595–605PubMed
20.
Zurück zum Zitat Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M (2002) Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 51:2241–2248PubMed Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M (2002) Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 51:2241–2248PubMed
21.
Zurück zum Zitat Mizutani M, Kern TS, Lorenzi M (1996) Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 97:2883–2890PubMed Mizutani M, Kern TS, Lorenzi M (1996) Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 97:2883–2890PubMed
22.
Zurück zum Zitat Hammes HP, Lin J, Wagner P et al (2004) Diabetes-induced angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 53:1104–1110PubMed Hammes HP, Lin J, Wagner P et al (2004) Diabetes-induced angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 53:1104–1110PubMed
23.
Zurück zum Zitat Bierhaus A, Schiekofer S, Schwaninger M et al (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50:2792–2808PubMed Bierhaus A, Schiekofer S, Schwaninger M et al (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50:2792–2808PubMed
24.
Zurück zum Zitat Stern D, Yan SD, Yan SF, Schmidt AM (2002) Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 54:1615–1625PubMed Stern D, Yan SD, Yan SF, Schmidt AM (2002) Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 54:1615–1625PubMed
25.
Zurück zum Zitat Hammes HP, Alt A, Niwa T, Bretzel RG, Brownlee M, Schleicher E (1999) Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 42:728–736PubMed Hammes HP, Alt A, Niwa T, Bretzel RG, Brownlee M, Schleicher E (1999) Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 42:728–736PubMed
26.
Zurück zum Zitat Kislinger T, Fu C, Huber B et al (1999) N(epsilon)–(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740–31749PubMed Kislinger T, Fu C, Huber B et al (1999) N(epsilon)–(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740–31749PubMed
27.
Zurück zum Zitat Schiekofer S, Andrassy M, Chen J et al (2003) Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 52:621–633PubMed Schiekofer S, Andrassy M, Chen J et al (2003) Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 52:621–633PubMed
28.
Zurück zum Zitat Quehenberger P, Bierhaus A, Fasching P et al (2000) Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 49:1561–1570PubMed Quehenberger P, Bierhaus A, Fasching P et al (2000) Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 49:1561–1570PubMed
29.
Zurück zum Zitat Hammes HP, Lin J, Renner O et al (2002) Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 51:3107–3112PubMed Hammes HP, Lin J, Renner O et al (2002) Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 51:3107–3112PubMed
30.
Zurück zum Zitat Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487PubMed Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487PubMed
31.
Zurück zum Zitat Miller JW, Adamis AP, Shima DT et al (1994) Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145:574–584PubMed Miller JW, Adamis AP, Shima DT et al (1994) Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145:574–584PubMed
32.
Zurück zum Zitat Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H (1995) Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res 27:48–52CrossRefPubMed Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H (1995) Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res 27:48–52CrossRefPubMed
33.
Zurück zum Zitat Ellis EA, Guberski DL, Somogyi-Mann M, Grant MB (2000) Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat. Free Radic Biol Med 28:91–101PubMed Ellis EA, Guberski DL, Somogyi-Mann M, Grant MB (2000) Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat. Free Radic Biol Med 28:91–101PubMed
34.
Zurück zum Zitat Gilbert RE, Vranes D, Berka JL et al (1998) Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 78:1017–1027PubMed Gilbert RE, Vranes D, Berka JL et al (1998) Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 78:1017–1027PubMed
35.
Zurück zum Zitat Sone H, Kawakami Y, Okuda Y et al (1997) Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia 40:726–730PubMed Sone H, Kawakami Y, Okuda Y et al (1997) Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia 40:726–730PubMed
36.
Zurück zum Zitat Stitt A, Gardiner TA, Alderson NL et al (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51:2826–2832PubMed Stitt A, Gardiner TA, Alderson NL et al (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51:2826–2832PubMed
37.
Zurück zum Zitat Kowluru RA, Odenbach S (2004) Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 53:3233–3238PubMed Kowluru RA, Odenbach S (2004) Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 53:3233–3238PubMed
38.
Zurück zum Zitat Maitra I, Serbinova E, Tritschler HJ, Packer L (1996) Stereospecific effects of R-lipoic acid on buthionine sulfoximine-induced cataract formation in newborn rats. Biochem Biophys Res Commun 221:422–429PubMed Maitra I, Serbinova E, Tritschler HJ, Packer L (1996) Stereospecific effects of R-lipoic acid on buthionine sulfoximine-induced cataract formation in newborn rats. Biochem Biophys Res Commun 221:422–429PubMed
Metadaten
Titel
Effect of R-(+)-α-lipoic acid on experimental diabetic retinopathy
verfasst von
J. Lin
A. Bierhaus
P. Bugert
N. Dietrich
Y. Feng
F. vom Hagen
P. Nawroth
M. Brownlee
H.-P. Hammes
Publikationsdatum
01.05.2006
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 5/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0174-y

Weitere Artikel der Ausgabe 5/2006

Diabetologia 5/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.